They are FDA-approved for type 2 diabetes and/or obesity
This suggests that retatrutide does not just reduce energy intake (calories in) but actively increases energy output (calories out), a dual-modality influence that tirzepatide does not theoretically possess to the same degree
The two pathways are independent and complementary
The specific site for administration may vary depending on factors such as individual preference, body mass, age, and any underlying medical conditions
Symptoms can include sharp pain, tingling, burning sensation, or simply exaggerated sensitivity to touch
FOXO4-DRI interferes with this binding, reactivating p53s apoptotic function and selectively eliminating senescent cells (1)